Sona Nanotech, Inc (TSE:SONA) has released an update.
Sona Nanotech Inc. reports positive interim results from a collaborative study with Dalhousie University, showing that their targeted hyperthermia therapy (THT), in combination with standard immunotherapy IL-2, has significantly improved treatment outcomes in a pre-clinical triple negative breast cancer model. The therapy not only shrunk tumors but also demonstrated a potential systemic immunogenic response. These promising findings suggest that Sona’s THT could potentially enhance the effectiveness of existing cancer treatments, with further studies planned to explore its impact on other cancer types and move towards human trials.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.
